MDMA therapy didn't get FDA approval. Now what?
The FDA declined to approve MDMA therapy for PTSD, requesting further studies due to clinical trial concerns. This setback is viewed as a delay, not a rejection, amid ongoing interest in psychedelics.
Read original article
The FDA has declined to approve MDMA therapy for treating post-traumatic stress disorder (PTSD), marking a setback for the psychedelic therapy movement. Lykos Therapeutics, which submitted the application, was asked to conduct an additional Phase 3 study due to concerns about the data provided. This decision comes despite previous optimism surrounding the potential approval, which was anticipated to allow healthcare professionals to prescribe MDMA therapy. The FDA's request for further study stems from criticisms regarding the clinical trial design, including issues with establishing placebo controls and ethical concerns raised during an advisory committee meeting. While the decision is disappointing for advocates of psychedelic therapy, it is viewed more as a delay than a definitive rejection. The approval of MDMA therapy would have challenged its classification as a Schedule I substance and could have paved the way for broader acceptance of psychedelics in medical treatment. The FDA's decision reflects ongoing caution in the regulatory landscape for mental health treatments, particularly those involving psychedelics. As the field continues to evolve, other organizations are also working on similar treatments, suggesting that the conversation around psychedelic therapy is far from over.
- The FDA has not approved MDMA therapy for PTSD, requesting further studies from Lykos Therapeutics.
- Concerns about clinical trial design and ethical practices influenced the FDA's decision.
- The setback is seen as a delay rather than a complete rejection of psychedelic therapy.
- Approval would have challenged MDMA's Schedule I classification and supported broader acceptance of psychedelics.
- Other organizations are pursuing similar treatments, indicating ongoing interest in psychedelic therapy.
Related
Top FDA official overrules staff to approve gene therapy that failed trial
The FDA approved Elevidys gene therapy for Duchenne muscular dystrophy, despite controversy over failed trials. Dr. Peter Marks led the decision, facing criticism for prioritizing emotional arguments over scientific evidence.
Next-generation psychedelics: should new agents skip the trip?
Companies are investing in next-generation psychedelics to enhance mental health treatment, focusing on reducing psychoactive effects while maintaining therapeutic benefits. Despite expanding interest and investments, questions persist about efficacy and cost-effectiveness.
Mexico has become a testing ground for psychedelic therapies
Mexico is a testing ground for psychedelic therapies like 5-MeO-DMT, attracting individuals seeking relief from conditions like depression and trauma. The trend reflects a global interest in alternative treatment modalities.
New study shows reactions in the brain in people who were given psilocybin
Researchers at Washington University studied psilocybin's impact on the brain using functional M.R.I. scans. Results in Nature showed significant changes in introspective brain areas. Psilocybin's effects lingered post-drug, hinting at mental health benefits beyond placebos.
A scientist took a psychedelic drug – and watched his own brain 'fall apart'
Researchers studied psilocybin's impact on the brain, finding it disrupts specific networks related to space, time, and self-awareness. This disruption enhances brain plasticity, potentially aiding in treating conditions like addiction and depression.
1 commentsRelated
Top FDA official overrules staff to approve gene therapy that failed trial
The FDA approved Elevidys gene therapy for Duchenne muscular dystrophy, despite controversy over failed trials. Dr. Peter Marks led the decision, facing criticism for prioritizing emotional arguments over scientific evidence.
Next-generation psychedelics: should new agents skip the trip?
Companies are investing in next-generation psychedelics to enhance mental health treatment, focusing on reducing psychoactive effects while maintaining therapeutic benefits. Despite expanding interest and investments, questions persist about efficacy and cost-effectiveness.
Mexico has become a testing ground for psychedelic therapies
Mexico is a testing ground for psychedelic therapies like 5-MeO-DMT, attracting individuals seeking relief from conditions like depression and trauma. The trend reflects a global interest in alternative treatment modalities.
New study shows reactions in the brain in people who were given psilocybin
Researchers at Washington University studied psilocybin's impact on the brain using functional M.R.I. scans. Results in Nature showed significant changes in introspective brain areas. Psilocybin's effects lingered post-drug, hinting at mental health benefits beyond placebos.
A scientist took a psychedelic drug – and watched his own brain 'fall apart'
Researchers studied psilocybin's impact on the brain, finding it disrupts specific networks related to space, time, and self-awareness. This disruption enhances brain plasticity, potentially aiding in treating conditions like addiction and depression.